Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Oct

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Sunvozertinib in Platinum-Pretreated NSCLC With EGFR Exon 20 Insertion Mutations

In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival

Kidney Cancer Cases Expected to Double by 2050

CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas

Variation in PSA Levels in Annual Testing Among Individuals Without Prostate Cancer Diagnosis